University of Texas Health Science Center Houston
Houston, Texas, 77030, United States
Location status: Recruiting
NCT Number: NCT03185702
The investigators will conduct genetic comparisons between Turner Syndrome (TS) patients with and without Bicuspid Aortic Valve (BAV) to identify causative agents of BAV in people with TS.
The investigators will correlate the patterns and prevalence of structural heart defects in TS women with emerging molecular data to identify patients who are at high risk for cardiovascular complications
Interested in participating?
Request InfoFemale
Observational
Houston, Texas, 77030, United States
Location status: Recruiting
Turner syndrome (TS) is a common chromosomal disorder that affects approximately 1 in 2500 live female births. Complete or partial monosomy of one of the X chromosomes in a female is associated with various congenital heart defects (CHDs), which include aortic dilatation, coarctation of aorta and BAV. Congenital cardiovascular defects related to CHD are the leading cause of death in women with TS. The Turner Syndrome Network Registry (TRN Registry) and genetic sample repository can address gaps in knowledge of CHD in TS by facilitating the recognition of demographic and genetic patterns. TRN Registry-based research can improve surveillance of TS patients who are at risk for CHD and provide valuable insight into genetic components of CHD.
The investigators will recruit TS patients into the TRN Registry and obtain blood and/or saliva samples after informed consent. The genetic diagnosis of TS will be confirmed using chromosomal microarrays. The array data will be also be used to identify genomic copy number variants, and rare variants in protein coding genes will be determined by exome sequencing. The investigators will derive induced pluripotent stem cells from some participants to determine why CHD is so prevalent in TS. CHD risk genes will be identified in comparisons between TS cases with and without congenital heart defects. To facilitate these comparisons, the investigators will abstract the demographic and medical data of registry participants from questionnaires and medical records. Imaging will be used to confirm the diagnosis of CHD and to determine the prevalence and severity of additional cardiovascular defects.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
Time frame: 10 years
Imaging data
Time frame: 10 years
Access to care and guideline-recommended care
Interested in participating?
Request InfoThe University of Texas Health Science Center, Houston
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02417740
Cardiovascular Abnormalities, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06507007
Cardiovascular Abnormalities, Cardiovascular Diseases
Herning, Denmark
View Trial DetailsNCT07221851
Bone Diseases, Bone Diseases, Developmental
Palo Alto, California, United States
View Trial DetailsNCT06834594
Adnexal Diseases, Cardiovascular Abnormalities
Kansas City, Missouri, United States
View Trial Details